2024
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure JACC State-of-the-Art Review
Newman J, O'Meara E, Böhm M, Savarese G, Kelly P, Vardeny O, Allen L, Lancellotti P, Gottlieb S, Samad Z, Morris A, Desai N, Rosano G, Teerlink J, Giraldo C, Lindenfeld J. Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2024, 83: 932-950. PMID: 38418008, DOI: 10.1016/j.jacc.2023.12.033.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAtrial fibrillationHeart failureAssociated with significant morbiditySpectrum of ejection fractionPrevention of AFIncidence of AFGuideline-directed therapyDiagnosis of AFEjection fractionSignificant morbidityMedical therapyJACC State-of-the-Art ReviewPatientsFrequent hospitalizationsIncreased life expectancyAssociated with greater symptom burdenCardiovascular conditionsGreater symptom burdenTherapySymptom burdenLife expectancyFibrillationHeartPrognosis
2023
Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
Faridi K, Desai N. Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease. American Journal Of Preventive Cardiology 2023, 14: 100491. PMID: 36969953, PMCID: PMC10036885, DOI: 10.1016/j.ajpc.2023.100491.Commentaries, Editorials and Letters
2022
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorQuadruple therapyOOP costsMedicare coveragePocket costsAngiotensin-converting enzyme inhibitorPrior authorizationAngiotensin receptor blockersQuadruple drug therapyCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsReduced ejection fractionDrug plansReceptor blockersEjection fractionHeart failureDrug therapyReceptor antagonistPrescription drug plansMedicare patientsEnzyme inhibitorsTherapyRegimensMedication prices
2020
Lipid Lowering Treatment Patterns and Risk of Subsequent Cardiovascular Outcomes Among Patients Initially Rejected for pcsk9 Inhibitor Therapy
Desai N, Rane P, Nunna S, Chen C, Exter J, Habib M, Zhou Z, Wade R. Lipid Lowering Treatment Patterns and Risk of Subsequent Cardiovascular Outcomes Among Patients Initially Rejected for pcsk9 Inhibitor Therapy. Journal Of Clinical Lipidology 2020, 14: 599-600. DOI: 10.1016/j.jacl.2020.05.086.Peer-Reviewed Original Research
2017
ADVANCED ANALYTICS PREDICTED OUTCOMES, IDENTIFIED CLINICALLY DISTINCT SUBGROUPS, AND DETECTED HETEROGENEITY IN RESPONSE TO THERAPY IN A COHORT OF MORE THAN 40,000 HEART FAILURE PATIENTS
Ahmad T, Rao P, Lund L, Warrier P, Rohit G, Desai N. ADVANCED ANALYTICS PREDICTED OUTCOMES, IDENTIFIED CLINICALLY DISTINCT SUBGROUPS, AND DETECTED HETEROGENEITY IN RESPONSE TO THERAPY IN A COHORT OF MORE THAN 40,000 HEART FAILURE PATIENTS. Journal Of The American College Of Cardiology 2017, 69: 2558. DOI: 10.1016/s0735-1097(17)35947-8.Peer-Reviewed Original Research
2013
VARIABILITY IN RESPONSE: PATTERNS IN PRESCRIBING ANTIPLATELET THERAPY AFTER CYP2C19 GENOTYPING AMONG PATIENTS WITH ACS AND PCI
Desai N, Canestaro W, Chaplin D, Martell L, Matlin O, Kyrychenko P, Brennan T, Choudhry N. VARIABILITY IN RESPONSE: PATTERNS IN PRESCRIBING ANTIPLATELET THERAPY AFTER CYP2C19 GENOTYPING AMONG PATIENTS WITH ACS AND PCI. Journal Of The American College Of Cardiology 2013, 61: e160. DOI: 10.1016/s0735-1097(13)60161-8.Peer-Reviewed Original Research